Intrexon Corp  

(Public, NYSE:XON)   Watch this stock  
Find more results for XON
-0.63 (-2.93%)
Apr 28 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 20.63 - 21.67
52 week 18.41 - 32.90
Open 21.53
Vol / Avg. 542,069.00/1.00M
Mkt cap 2.40B
P/E     -
Div/yield     -
EPS -1.58
Shares 118.73M
Beta 1.53
Inst. own 87%
Jun 9, 2017
Intrexon Corp Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 24, 2017
Intrexon Corp at B. Riley Investor Conference Add to calendar
May 8, 2017
Q1 2017 Intrexon Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 1, 2017
Q4 2016 Intrexon Corp Earnings Call
Mar 1, 2017
Q4 2016 Intrexon Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -88.57% -88.60%
Operating margin -70.84% -65.56%
EBITD margin - -52.69%
Return on average assets -16.72% -17.52%
Return on average equity -30.50% -29.76%
Employees 832 -
CDP Score - -


1750 Kraft Dr Ste 1400
BLACKSBURG, VA 24060-6147
United States - Map
+1-301-5569809 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Officers and directors

Randal J. Kirk Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Thomas D. Reed Ph.D. Founder, Chief Science Officer
Age: 49
Bio & Compensation  - Reuters
Rick L. Sterling CPA Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Andrew J. Last Ph.D. Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Joel Liffmann Senior Vice President - Finance
Bio & Compensation  - Reuters
Jack Anthony Bobo Senior Vice President, Chief Communications Officer
Age: 49
Bio & Compensation  - Reuters
Ena Chan Cratsenburg Senior Vice President - Consumer Sector
Bio & Compensation  - Reuters
Corey Huck senior Vice President, Food Sector
Bio & Compensation  - Reuters
Suma M. Krishnan Senior Vice President, Product Development & Head of Human Therapeutics Division
Age: 50
Bio & Compensation  - Reuters
Nir Nimrodi Senior Vice President - Corporate Development and Environment Sector
Age: 45
Bio & Compensation  - Reuters